Chinese market

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital 'remains confident' in iX Biopharma’s growth prospects upon China agreement

PhillipCapital has kept its "buy" recommendation with the same target price of 44.5 cents.

China Focus

China's coupon-led recovery

Local Chinese governments have distributed about RMB4 billion ($807.6 million) of digital coupons in the past few days.

Commentary

Reassessment of investing strategies required as investment sands are shifting

SINGAPORE (Apr 15): Where do I allocate my long-term investment capital to maximise growth? Globalisation offered many opportunities and a means to diversify risk. It made sense to allocate funds to US markets and to the fast-rising Chinese markets. I, li
×